MCM
VRTX icon

Mitchell Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Mitchell Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,128
Closed -$454K – 120
2024
Q4 		$454K Sell
1,128
-14,325
-93% -$6.64M 0.08% 85
2024
Q3 		$7.19M Sell
15,453
-515
-3% -$247K 1.26% 24
2024
Q2 		$7.48M Buy
15,968
+271
+2% +$118K 1.32% 20
2024
Q1 		$6.56M Buy
15,697
+4,086
+35% +$1.73M 1.26% 22
2023
Q4 		$4.72M Buy
11,611
+53
+0.5% +$19.6K 0.99% 33
2023
Q3 		$4.02M Sell
11,558
-33
-0.3% -$11.5K 0.95% 35
2023
Q2 		$4.08M Sell
11,591
-334
-3% -$113K 0.93% 37
2023
Q1 		$3.76M Buy
11,925
+28
+0.2% +$8.4K 0.93% 37
2022
Q4 		$3.44M Sell
11,897
-22
-0.2% -$6.71K 0.95% 34
2022
Q3 		$3.45M Buy
11,919
+93
+0.8% +$26.8K 0.98% 29
2022
Q2 		$3.33M Buy
+11,826
New +$3.17M 0.93% 34

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Mitchell Capital Management's VRTX Position: Q1 2025 in Review

Mitchell Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q1 2025, closing a stake of 1,128 shares — an estimated $454K sold.

Mitchell Capital Management first reported a position in VRTX in Q2 2022 and held it in 11 quarters. The position peaked at $7.48M in Q2 2024. 1,612 funds tracked by Wall St. Rank hold VRTX as of Q1 2025.

  • Mitchell Capital Management reported no remaining Vertex Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Mitchell Capital Management sold 1,128 Vertex Pharmaceuticals shares in Q1 2025, an estimated $454K.
  • Mitchell Capital Management first reported a position in Vertex Pharmaceuticals in Q2 2022 and held it in 11 quarters.
  • Mitchell Capital Management's Vertex Pharmaceuticals position peaked at $7.48M in Q2 2024.
  • 1,612 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2025.

Based on Mitchell Capital Management's 13F filing for Q1 2025, filed 9 May 2025.